Key result
A clinical model and hs-cTnT predict extensive LGE in non-high-risk HCM with a ~0.87 c-statistic.
Why the study?
In nonhigh risk hypertrophic cardiomyopathy patients, the ability to predict extensive myocardial fibrosis by clinical variables and biomarkers to guide CMR imaging was unclear.
Do clinical variables and biomarkers predict extensive myocardial fibrosis in nonhigh risk patients with hypertrophic cardiomyopathy?
Observational (n=98)
Do clinical variables and biomarkers predict extensive myocardial fibrosis in nonhigh risk patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In nonhigh risk patients with hypertrophic cardiomyopathy, clinical variables combined with hs-cTnT can effectively predict or exclude extensive myocardial fibrosis, potentially optimizing the use of CMR imaging.
In nonhigh risk patients with hypertrophic cardiomyopathy (HC), the presence of extensive late gadolinium enhancement (LGE ext ) at cardiovascular magnetic resonance (CMR) imaging has been proposed as a risk modifier in the decision process for implantable cardioverter defibrillator implantation. With a pretest risk of about 10%, a strategy that alters the likelihood of LGE ext could markedly affect efficacious CMR imaging. Our aim was to study the potential of clinical variables and biomarkers to predict LGE ext . In 98 HC patients without any clear indication for implantable cardioverter defibrillator implantation, we determined the discriminative values of a set of clinical variables and a panel of biomarkers (hs-cTnT, NTproBNP, GDF-15, and Gal-3, CICP) for LGE ext , that is, LGE ≥15% of the left ventricular mass. LGE ext was present in 10% (10/98) of patients. The clinical prediction model contained a history of nonsustained ventricular tachycardia, maximal wall thickness and reduced systolic function (c-statistic: 0.868, p <0.001). Of all biomarkers, only hs-cTnT was associated with LGE ext , in addition to the improved clinical model of diagnostic accuracy (p = 0.04). A biomarker-only strategy allowed the exclusion of LGE ext in half of the cohort, in case of a hs-cTnT concentration less than the optimal cutoff (Youden index; 8 ng/L—sensitivity 100%, specificity 54%). In conclusion, in this nonhigh risk HC cohort, the pretest likelihood of LGE ext can be altered using clinical variables and the addition of hs-cTnT. The promising findings with the use of hs-cTnT only call for new initiatives to study its impact on efficacious CMR imaging in a larger HC population, either with or without additional use of clinical variables.
No takes yet. Share an insight, caveat, or question.
Gommans et al. (2018) conducted an observational in Hypertrophic cardiomyopathy (n=98). Clinical variables and hs-cTnT was evaluated on Extensive late gadolinium enhancement (LGE ≥15% of left ventricular mass) (c-statistic 0.868, p=<0.001). A clinical prediction model and hs-cTnT accurately predicted extensive late gadolinium enhancement in nonhigh risk patients with hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: